Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection
- PMID: 29346085
- PMCID: PMC5807223
- DOI: 10.1016/j.jcv.2018.01.003
Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection
Abstract
Background: Assays that detect HIV antigen (Ag) and antibody (Ab) can be used to screen for HIV infection.
Objectives: To compare the performance of the BioPlex 2200 HIV Ag-Ab assay and two other Ag/Ab combination assays for detection of acute HIV infection.
Study design: Samples were obtained from 24 individuals (18 from the US, 6 from South Africa); these individuals were classified as having acute infection based on the following criteria: positive qualitative RNA assay; two negative rapid tests; negative discriminatory test. The samples were tested with the BioPlex assay, the ARCHITECT HIV Ag/Ab Combo test, the Bio-Rad GS HIV Combo Ag-Ab EIA test, and a viral load assay.
Results: Twelve (50.0%) of 24 samples had RNA detected only ( > 40 to 13,476 copies/mL). Ten (43.5%) samples had reactive results with all three Ag/Ab assays, one sample was reactive with the ARCHITECT and Bio-Rad assays, and one sample was reactive with the Bio-Rad and BioPlex assays. The 11 samples that were reactive with the BioPlex assay had viral loads from 83,010 to >750,000 copies/mL; 9/11 samples were classified as Ag positive/Ab negative by the BioPlex assay.
Conclusions: Detection of acute HIV infection was similar for the BioPlex assay and two other Ag/Ab assays. All three tests were less sensitive than a qualitative RNA assay and only detected HIV Ag when the viral load was high. The BioPlex assay detected acute infection in about half of the cases, and identified most of those infections as Ag positive/Ab negative.
Keywords: Acute; Ag/Ab assay; BioPlex; HIV.
Copyright © 2018 Elsevier B.V. All rights reserved.
Conflict of interest statement
Competing interests: None of the authors has a financial or personal relationship with other people or organizations that could inappropriately influence (bias) their work, with the following exception: Dr. Eshleman has collaborated on research studies with Abbott Molecular; the company has provided reagents for research projects.
Similar articles
-
Decreased Seroreactivity in Individuals Initiating Antiretroviral Therapy during Acute HIV Infection.J Clin Microbiol. 2019 Sep 24;57(10):e00757-19. doi: 10.1128/JCM.00757-19. Print 2019 Oct. J Clin Microbiol. 2019. PMID: 31217270 Free PMC article.
-
Performance of the fourth-generation Bio-Rad GS HIV Combo Ag/Ab enzyme immunoassay for diagnosis of HIV infection in Southern Africa.J Clin Virol. 2015 Jan;62:75-9. doi: 10.1016/j.jcv.2014.11.023. Epub 2014 Nov 27. J Clin Virol. 2015. PMID: 25542477 Free PMC article.
-
Comparative evaluation of three FDA-approved HIV Ag/Ab combination tests using a genetically diverse HIV panel and diagnostic specimens.J Clin Virol. 2017 Jul;92:62-68. doi: 10.1016/j.jcv.2017.05.005. Epub 2017 May 13. J Clin Virol. 2017. PMID: 28535437
-
Performance comparison of the 4th generation Bio-Rad Laboratories GS HIV Combo Ag/Ab EIA on the EVOLIS™ automated system versus Abbott ARCHITECT HIV Ag/Ab Combo, Ortho Anti-HIV 1+2 EIA on Vitros ECi and Siemens HIV-1/O/2 enhanced on Advia Centaur.J Clin Virol. 2013 Dec;58 Suppl 1:e79-84. doi: 10.1016/j.jcv.2013.08.009. J Clin Virol. 2013. PMID: 24342482
-
Performance evaluation of the Bio-Rad Laboratories GS HIV Combo Ag/Ab EIA, a 4th generation HIV assay for the simultaneous detection of HIV p24 antigen and antibodies to HIV-1 (groups M and O) and HIV-2 in human serum or plasma.J Clin Virol. 2011 Dec;52 Suppl 1:S57-61. doi: 10.1016/j.jcv.2011.09.023. Epub 2011 Oct 12. J Clin Virol. 2011. PMID: 21995929
Cited by
-
Effect of an opt-out point-of-care HIV-1 nucleic acid testing intervention to detect acute and prevalent HIV infection in symptomatic adult outpatients and reduce HIV transmission in Kenya: a randomized controlled trial.HIV Med. 2022 Jan;23(1):16-28. doi: 10.1111/hiv.13157. Epub 2021 Aug 25. HIV Med. 2022. PMID: 34431196 Free PMC article. Clinical Trial.
-
Data on the relationship of signal-to-cutoff ratio of two HIV antigen/antibody combination assays to subsequent confirmation of HIV-1 infection in a low-prevalence population.Data Brief. 2020 May 16;31:105707. doi: 10.1016/j.dib.2020.105707. eCollection 2020 Aug. Data Brief. 2020. PMID: 32462068 Free PMC article.
-
Decreased Seroreactivity in Individuals Initiating Antiretroviral Therapy during Acute HIV Infection.J Clin Microbiol. 2019 Sep 24;57(10):e00757-19. doi: 10.1128/JCM.00757-19. Print 2019 Oct. J Clin Microbiol. 2019. PMID: 31217270 Free PMC article.
-
BioRad BioPlex® HIV Ag-Ab assay: Incidence of false positivity in a low-prevalence population and its effects on the current HIV testing algorithm.J Clin Virol. 2019 Jul;116:1-3. doi: 10.1016/j.jcv.2019.04.002. Epub 2019 Apr 6. J Clin Virol. 2019. PMID: 30981082 Free PMC article.
-
p24 revisited: a landscape review of antigen detection for early HIV diagnosis.AIDS. 2018 Sep 24;32(15):2089-2102. doi: 10.1097/QAD.0000000000001982. AIDS. 2018. PMID: 30102659 Free PMC article. Review.
References
-
- World Health Organization. Consolidated guidelines on HIV testing. 2015 Available at: http://who.int/hiv/pub/guidelines/hiv-testing-services/en/. Accessed: 1 November, 2017.
-
- Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory testing for the diagnosis of HIV infection: updated recommendations. 2014 Available at: http://dx.doi.org/10.15620/cdc.23447. Accessed: 1 November, 2017. - DOI
-
- Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. J Infect Dis. 2010;202(Suppl 2):S270–7. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources